Table 2.
Ondansetron population pharmacokinetic parameter estimates.
| Parameters | Point estimate (%SE) |
Symmetrical 95% CI |
Nonsymmetrical 95% CI |
Residual variability (%CV) |
Between-subject variability (%CV) |
|---|---|---|---|---|---|
| Women: | 21.6 | ||||
| CL (L/h) | 40.1 | ||||
| CL0 | 21.8 (6.7) | 18.9, 24.6 | 17.2, 27.2 | ||
| θCL | 0.69 (11) | 0.54, 0.84 | 0.52, 0.92 | ||
| V (L) | 27.9 (17) | 18.5, 37.3 | 13.6, 45.0 | 56.1 | |
| Q(L/h) | 329 (9.5) | 268, 390 | 256, 401 | 51.3 | |
| VSS (L) | 32.4 | ||||
| VSS0 | 167 (4.7) | 151, 182 | 140, 198 | ||
| θVss | 0.75 (7.8) | 0.63, 0.86 | 0.61, 0.91 | ||
| Cord: | 23.5 | ||||
| KP | 0.47 (5.1) | 0.42, 0.52 | 0.44, 0.51 | ||
| Neonates: | 21.9 | ||||
| KN0 (1/h) | 0.046 (6.2) | 0.041, 0.052 | 0.040, 0.052 | 29.6 | |
%SE: relative standard error; CV: coefficient of variation; CI: confidence interval; CL clearance in women; CL0 clearance for 4-mg dose; θCL fractional change in CL0 for the 8-mg dose; V distribution volume in women; Q inter-compartmental clearance in women; KP placenta-to-